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Abstract Cathepsin C was purified from human spleen by a 
rapid procedure, which included homogenization, ammonium 
sulfate precipitation, gel filtration on Sephacryl S-200 and fmally 
affinity chromatography on chicken cystatin-Sepharose. The 
interaction between cathepsin C and chicken cystatin was further 
characterized. It was found to be accompanied by a maximum 
decrease in fluorescence mission intensity at 330 nm. Fluores- 
cence titration showed that human catbepsin C can bind four 
chicken cystatin molecules. The 4:1 binding stoichiometry was 
confirmed by titration monitored by the loss of enzyme activity. 
A non-competitive-competitive ype of inhibition was determined 
from a double-reciprocal Lineweaver-Burk plot with a Kj value of 
0.22 nM for the non-competitive inhibition. 
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1. Introduction 
Cathepsin C or dipeptidyl aminopeptidase I (EC 3.4.14.1) is 
a lysosomal cysteine proteinase and belongs to the papain 
family [1]. Like other cysteine proteinases cathepsin C is in- 
volved in intracellular protein degradation [2] and is found in 
a variety of human and rat tissues [3]. Cathepsin C is an 
oligomeric enzyme, consisting of four identical subunits, 
each consisting of a heavy and a light chain and a large pro- 
region part, thus differing from other papain-like cysteine 
proteinases [4]. It is active in the pH range between 3.5 and 
8.0 [5] and cleaves peptides and proteins with an unsubstituted 
amino terminus [6-11], as well as certain synthetic substrates 
with a blocked amino terminus [12]. 
Cathepsin C is inhibited by stefins A and B [13-15] and 
chicken cystatin [13,16], three protein inhibitors of cysteine 
proteinases from the cystatin superfamily [17]. All inhibitors 
were shown to be of the competitive, reversible type, with 
stefin A being the weakest by 2-3 orders of magnitude [13- 
16]. However, the mechanism of interaction between cathepsin 
C and cystatins is not known. 
Herein we describe a new, efficient method for isolating 
cathepsin C, based on the interaction between the enzyme 
and chicken cystatin, A further goal was to determine the 
binding stoichiometry between these two proteins, since cathe- 
psin C is an oligomeric enzyme. 
2. Materials and methods 
2.1. Materials 
Sephacryl S-200, activated CH-Sepharose 4B and low molecular 
mass standards were from Pharmacia (Sweden), Ser-Tyr-~NA and 
Gly-Phe-4M[3NA were from Bachem (Switzerland), and DTE and 
EDTA were from Serva (Germany). Stock solutions of substrates 
were prepared in dimethylsulfoxide (Merck, Germany). Chicken cy- 
statin was purified [18] and titrated with active-site titrated papain 
[19]. Chicken cystatin-Sepharose 4B affinity chromatography gel was 
prepared using activated CH-Sepharose 4B following the manufac- 
turer's instructions. Protein concentrations were determined by the 
Bio-Rad (USA) Protein Assay [20]. All other chemicals were of ana- 
lytical grade. All the kinetic experiments were performed in 100 mM 
phosphate buffer, pH 6.0, containing 100 mM NaCI, 1 mM EDTA 
and 2 mM DTE, at 25°C. 
2.2. Purification procedure 
Human cathepsin C was purified from human spleen by a proce- 
dure modified from that reported previously for purification from 
human kidney, which included homogenization, ammonium sulfate 
precipitation, ion-exchange chromatography on CM Sephadex C-50 
column, gel filtration on Sephacryl S-200 column, affinity chromato- 
graphy on thiol-Sepharose 4Band ion-exchange chromatography on a 
Q-Sepharose FF column [4]. Following homogenization a d ammo- 
nium sulfate precipitation, the sample was directly applied on a Se- 
phacryl S-200 (Pharmacia, Sweden) column (3 x 140 cm). Cathepsin 
C-containing fractions were pooled, concentrated and then applied to 
a chicken cystatin-Sepharose column (1.5 × 10 cm), equilibrated with 
100 mM piperazine buffer pH 5.0 containing 100 mM NaC1 and 1 mM 
EDTA. After thorough washing of the column with the same buffer, 
cathepsin C was eluted with 5 mM citric acid, pH 3.5. 5-ml fractions 
were collected and the pH immediately adjusted to pH 6.0 with 1 M 
Bis-Tris buffer (pH 6.0). Fractions with A2s0 > 0.05 were pooled, con- 
centrated and dialyzed against 100 mM acetate buffer, pH 5.0 con- 
taining 300 mM NaCI and 1 mM EDTA. Cathepsin C was stored at 
4°C. 
2.3. SDS-PAGE 
SDS-PAGE was performed on a PhastSystem (Pharmacia, Sweden) 
using an 8-25% gradient gel following the manufacturer's in tructions. 
2.4. Fluorescence measurements 
Fluorescence measurements were performed in a Perkin-Elmer LS- 
50 spectrofluorimeter (UK) using an excitation wavelength of280 nm. 
Cells with 1 cm path lengths were used. The excitation and emission 
bandwidths were 5 and 10 nm, respectively. Titration of cathepsin C
with chicken cystatin was performed as described previously for other 
cysteine proteinase-cystatin interactions [21,22] by monitoring the de- 
crease in fluorescence emission intensity accompanying the interaction 
at 330 nm, where the maximum fluorescence change was observed (see 
Section 3). The final concentration f cathepsin C was 11.5 nM. The 
binding curve was analysed by non-linear regression analysis to the 
equilibrium binding equation [23]. 
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2.5. Titration of cathepsin C by the loss of enzymatic activity 
Enzymatic titrations of cathepsin C with chicken cystatin were per- 
formed similarly to the procedure described earlier [19]. Cathepsin C
(11.5 nM final concentration) was added to 200 ~tl of reaction buffer, 
followed 5 min later by the addition of 300 ixl of chicken cystatin 
(various concentrations) in the same buffer. After 30 min of incuba- 
tion at 25°C, 100 tll of 150 ktM Ser-Tyr-[3NA in the same buffer were 
added. The release of product was monitored with a Perkin-Elmer 
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spectrofluorimeter. Residual activities were determined by linear re- 
gression analysis and the binding stoichiometry was then determined 
by non-linear regression analysis of the data to the theoretical binding 
equation [24]. 
In order to determine inhibition constants and type of inhibition, 
experiments were performed essentially as described above, except 
that cathepsin C and chicken cystatin were used at much lower con- 
centrations (0.01 and 0q3.088 nM final concentrations, respectively). 
In addition, substrate concentration was varied (1-120 ~tM final con- 
centration). 
3. Results and discussion 
Cathepsin C was purified to homogeneity from human 
spleen by a simple and rapid method based on affinity chro- 
matography on immobilized chicken cystatin. After solubili- 
zation of lysosomal enzymes, the high-molecular mass cathe- 
psin C (200 kDa) was separated from other lower molecular 
mass proteins. In the final step active cathepsin C was sepa- 
rated by affinity chromatography. A product gave a pattern 
on SDS-PAGE (Fig. 1) which was identical with that obtained 
for the enzyme prepared by using the earlier method [4], in- 
dicating that the isolated enzyme was pure. Cathepsin C is an 
oligomeric enzyme, each subunit consisting from three differ- 
ent polypeptide chains [4]. From 500 g of spleen we obtained 
8 mg of cathepsin C. This is a much higher yield than those 
obtained by other methods, which included several chroma- 
tography steps [4,25,26]. The main advantage of this proce- 
kDa 
93  - 
67  - 
43  - 
30  - 
20 .1  - 
14 .4  - 
Fig. 1. SDS-PAGE of human cathepsin C after the affinity chroma- 
tography step. Lanes: 1, standards; 2, human cathepsin C under re- 
ducing conditions; 3, human cathepsin C under nonreducing condi- 
tions. 
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Fig. 2. Fluorescence emission spectra of chicken cystatin (. - • ), hu- 
man cathepsin C (- - - ), the complex between cathepsin C and cy- 
statin ( ), and the sum of spectra for cathepsin C and cystatin 
(' ' -).  The concentrations of cathepsin C and cystatin were 11.5 and 
46 nM, respectively. 
dure, however, is its rapidity, which allows larger quantities of 
the enzyme to be purified in a short time. Since chicken cy- 
statin is known as a good inhibitor of various cysteine pro- 
teinases, this method may well serve as a tool for the rapid 
purification of other papain-like cysteine proteinases. 
We have studied the mechanism of interaction between 
chicken cystatin and cathepsin C by various methods. Binding 
of chicken cystatin to cathepsin C resulted in a decrease of 
fluorescence emission intensity (Fig. 2). The largest decrease 
of intensity due to complex formation was observed between 
330 and 340 nm. This suggests that some of the Trp residues 
of enzyme and inhibitor are involved in the interaction. From 
previous studies it is known that Trp 104 of chicken cystatin 
and Trp 26, Trp 60 and Trp 177 of papain [21,27,28] are involved 
in the enzyme-inhibitor interaction. However, the fluorescence 
intensity accompanying the interaction decreased only by 28% 
(at 330 nm), which is substantially ess than for the chicken 
cystatin/papain teraction [21]. Nevertheless, the value is 
comparable to those of other chicken cystatin/cathepsin inter- 
actions (B. Turk, unpublished results). This difference could 
be explained by Trp26Tyr and Trp69Tyr substitutions (papain 
numbering) in cathepsin C [29]. 
Fluorescence titration of cathepsin C with chicken cystatin, 
standardized with highly active papain, gave an apparent 
chicken cystatin/cathepsin C binding stoichiometry of 
3.4 + 0.1 (Fig. 3a). The result thus indicates four inhibitor 
binding sites on each cathepsin C molecule, in agreement 
with the previous tudy [4], which showed four substrate bind- 
ing sites on each cathepsin C molecule. The observed binding 
stoichiometry most likely reflects the presence of some inactive 
material in the cathepsin C preparation. Despite the low pro- 
tein concentrations u ed, it was impossible to determine the 
Kd values with good precision. Nevertheless, from the shape 
of the curve it can be concluded that the Kd values are -<2 
nM, although it is impossible to distinguish between the Kd 
values for individual binding sites. 
To confirm the above results, titration of cathepsin C with 
chicken cystatin was monitored by the loss of enzymatic ac- 
tivity against synthetic substrates. As can be seen in Fig. 3b, 
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3.5+0.1 mol of inhibitor were needed to saturate 1 mol of 
cathepsin C, in agreement with the results on fluorescence 
titration. 
In order to determine the type of inhibition of cathepsin C
by chicken cystatin, their interaction was studied at different 
substrate and inhibitor concentrations. The rates of product 
formation are shown in double-reciprocal Lineweaver-Burk 
plots (Fig. 4). Lines 1-3 show non-competitive inhibition (in- 
tercept on the baseline) and lines 3-5 exhibit competitive in- 
hibition (intercept on the vertical axis). For reasons of clarity 
all the data have not been presented in Fig. 4. All the plots of 
l/v vs. [I] (Dixon plot) exhibited a downward curvature at 
higher inhibitor concentrations (not shown). According to 
Dixon [30], such an inhibition type can be described as a 
non-competitive-competitive one,i.e. non-competitive at low 
and competitive at high ligand concentrations. Under non- 
competitive conditions, an approximate Ki value of 0.22 nM 
was determined for the human cathepsin C-chicken cystatin 
interaction from the plot of l/v vs. 1/[S] [30]. At higher sub- 
strate and inhibitor concentrations, however, the system be- 
comes too complex to allow determination of individual Kd 
values for the other binding sites. 
In conclusion, cathepsin C was purified from human spleen 
by a modified method, where the most important step is affin- 
ity chromatography on immobilized chicken cystatin. Various 
titrations howed that one molecule of human cathepsin C can 
simultaneously bind four chicken cystatin molecules. The type 
of inhibition was determined to be non-competitive-competi- 
tive. 
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Fig. 3. Titration of human cathepsin C (11.5 nM) with chicken cy- 
statin. (A) Monitored by measurements of tryptophan fluorescence. 
Ft, fluorescence of added chicken cystatin; F0, fluorescence of ca- 
thepsin C; F, fluorescence of cystatin-cathepsin C mixture. Fitted 
curve was generated by nonlinear regression analysis [23]. (B) in the 
presence of substrate, monitored by measurements of the loss of en- 
zyme activity. Fitted curve was generated by nonlinear egression 
analysis [24]. 
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Fig. 4. Lineweaver-Burk plots for the inhibition of human cathepsin 
C with chicken cystatin. Line 1 represents cathepsin C activity (0.01 
nM) in the absence of inhibitor. Lines 2-5 show the enzyme activity 
in the presence of 0.011, 0.022, 0.066, and 0.088 nM cystatin, re- 
spectively. 
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